Working… Menu

Capsaicin Patch 8 % for the Treatment of Persistent Pain After Inguinal Herniotomy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01699854
Recruitment Status : Terminated (Expiration of the placebo patch)
First Posted : October 4, 2012
Last Update Posted : February 26, 2014
Information provided by (Responsible Party):
Joakim Bischoff, Rigshospitalet, Denmark

Brief Summary:
In the present study the investigators intend to investigate analgesic and sensory effects of a capsaicin patch 8 %(Qutenza) in patients with severe post-herniotomy pain and sensory abnormalities in the skin.

Condition or disease Intervention/treatment Phase
Persistent Pain After Inguinal Herniotomy Drug: capsaicin patch (qutenza) Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Study Start Date : August 2012
Actual Primary Completion Date : September 2013
Actual Study Completion Date : September 2013

Resource links provided by the National Library of Medicine

Drug Information available for: Capsaicin

Arm Intervention/treatment
Active Comparator: capsaicin patch Drug: capsaicin patch (qutenza)
Placebo Comparator: placebo patch Drug: Placebo

Primary Outcome Measures :
  1. Pain change capsaicin vs. placebo patch treatment [ Time Frame: Pain intensity assessed at baseline and at 1,2,3 months follow-up ]
    Summed pain intensity (SPI) is calculated as median pain intensities at rest, during transition from the supine lying to the standing erect position, and auto-palpation twice each day for the last 3 days at baseline and at 1 months, 2 months and 3 months during follow-up. The primary outcome measure is the maximum difference between the summed pain intensity differences (SPID) for the phases: Baseline, 1 month, 2 month or 3 month. Δ SPID is then calculated as the difference in SPID between capsaicin and placebo treated patients.

Secondary Outcome Measures :
  1. Changes in AAS (Activities Assessment Scale) score
  2. Changes in HADS (Hospital Anxiety and Depression Scale) score
  3. Changes in QST (Quantitative sensory testing)
  4. Changes in sleep (Sleep Interference Scale) score
  5. Changes in S-LANSS (Leeds self-assessment of neuropathic symptoms and signs)
  6. Changes in intraepidermal nerve fiber density
  7. Subgroup analysis for pain change(summed pain intensity differences (SPID) capsaicin patch vs. placebo are made for patients with thermal hypoesthesia and thermal normo/hyperesthesia
  8. Changes in PCS (Pain Catastrophizing Scale) score

Other Outcome Measures:
  1. interim analyses
    An interim analysis evaluating pain change (SPID) for capsaicin patch vs. placebo treatment by an independent statistician following completion of 32 patients.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients ASA (American Society´s of Anesthesiology´s classification) scores I-III
  • Severe post-herniotomy pain for more than six months and with severe pain (numerical rating scale [NRS] 0-10 points) during rest or during movement > 5.

Exclusion Criteria:

  • History of an allergic reaction or intolerance to capsaicin or vehicle ingredients in the patches
  • Severe cardiac impairment, e.g., NYHA (New York Heart Association) Class ≥ III
  • Inflamed or injured skin at the application site
  • Signs of cognitive impairment
  • Known drug or ethanol abuse

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01699854

Layout table for location information
Copenhagen, Copenhagen Ø, Denmark, 2100
Sponsors and Collaborators
Rigshospitalet, Denmark
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Joakim Bischoff, MD, Rigshospitalet, Denmark Identifier: NCT01699854    
Other Study ID Numbers: H-4-2012-055
2012-001540-22 ( EudraCT Number )
First Posted: October 4, 2012    Key Record Dates
Last Update Posted: February 26, 2014
Last Verified: February 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Dermatologic Agents
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs